Equities Analysts Set Expectations for ADIL Q1 Earnings

Posted by ABMN Staff on Mar 22nd, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Equities researchers at Litchfield Hills Research increased their Q1 2025 earnings per share estimates for shares of Adial Pharmaceuticals in a report released on Tuesday, March 18th. Litchfield Hills Research analyst T. O’neill now expects that the company will earn ($0.37) per share for the quarter, up from their previous forecast of ($0.40). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.22) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.23.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock opened at $0.74 on Thursday. The company has a market cap of $4.87 million, a price-to-earnings ratio of -0.22 and a beta of 1.13. The stock has a 50 day simple moving average of $0.82 and a 200-day simple moving average of $0.96. Adial Pharmaceuticals has a 1-year low of $0.61 and a 1-year high of $3.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its stake in Adial Pharmaceuticals by 63.8% in the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock valued at $55,000 after purchasing an additional 21,238 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Adial Pharmaceuticals in the 4th quarter valued at $48,000. Finally, Geode Capital Management LLC raised its stake in Adial Pharmaceuticals by 36.0% in the 4th quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock valued at $62,000 after purchasing an additional 16,381 shares during the last quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

Adial Pharmaceuticals Company Profile

(Get Free Report)

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.